版本:
中国

BRIEF-FDA grants priority review to Merck's supplemental biologics license application (SBLA) for Keytruda

Nov 28 Merck & Co Inc

* FDA grants priority review to Merck's supplemental biologics license application (SBLA) seeking approval for Keytruda(pembrolizumab) for new indication in microsatellite instability-high cancer Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐